Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Are there specific excipients that significantly affect tigecycline's pharmacokinetics?What sets aurobindo's clonazepam manufacturing apart for potency?Does aurobindo's manufacturing impact clonazepam's distribution?Can yoga affect lipitor's potency or side effects?How do clinical trials prove polivy's effectiveness?
See the DrugPatentWatch profile for Ocrevus
Efficacy of Ocrevus in Reducing Disease Activity Ocrevus (ocrelizumab) has been shown to be effective in reducing disease activity in patients with multiple sclerosis (MS). [1] It was approved by the FDA in 2017 for the treatment of people with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Reduction in Disability Progression Studies have demonstrated that Ocrevus can reduce disability progression and slow disease activity in patients with MS. The phase III trials, OCREVUS-303 and OCREVUS-305, showed that patients treated with Ocrevus had a 47% reduction in the risk of 12-week confirmed disability progression compared to Avonex (interferon beta-1a) and Rebif (interferon beta-1a). [1] Relapse Rate Reduction Ocrevus has also been shown to reduce the relapse rate in patients with RMS. In the OCREVUS-303 trial, patients treated with Ocrevus had a 47% reduction in annualized relapse rate (ARR) compared to Avonex and Rebif. [1] Effectiveness in PPMS In the OCREVUS-305 trial, Ocrevus was shown to reduce disability progression in patients with PPMS compared to placebo. Patients treated with Ocrevus had a 25% reduction in the risk of 12-week confirmed disability progression compared to placebo. [1] Adverse Effects While Ocrevus has been shown to be effective in reducing disease activity in patients with MS, it is not without potential adverse effects. Common side effects include infusion reactions, upper respiratory tract infections, and herpes infections. [1] Patent Expiration The patent for Ocrevus is set to expire in 2031, which may lead to the availability of biosimilars and generic alternatives. [2] Regulatory Status Ocrevus has been approved by regulatory agencies worldwide, including the FDA, EMA, and TGA, for the treatment of RMS and PPMS. [1] Clinical Data The clinical data for Ocrevus has been published in various peer-reviewed journals, including the New England Journal of Medicine and the Lancet Neurology. [1] Sources: [1] https://www.drugpatentwatch.com/drug/ocrevus [2] https://www.drugpatentwatch.com/patent/US10281358B2 Note: This article contains affiliate links to DrugPatentWatch.com.
Other Questions About Ocrevus :